All Stories

  1. Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy
  2. 17th International Conference on Malignant Lymphoma: Key Takeaways
  3. Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents
  4. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
  5. Extranodales Marginalzonenlymphom des mukosaassoziierten lymphatischen Gewebes (MALT-Lymphom)
  6. D max : A simple and reliable PET/CT‐derived new biomarker of lymphoma outcome?
  7. Finding a consensus on time‐to‐event endpoints definitions in marginal zone lymphoma: A Delphi method
  8. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study
  9. Marginal-Zone Lymphomas
  10. PET imaging of lymphomas
  11. Radiomics in Malignant Lymphomas
  12. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas
  13. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial
  14. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
  15. Foreword
  16. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
  17. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma
  18. Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
  19. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
  20. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review
  21. Novel acquisitions on biology and management of transformed follicular lymphoma
  22. Recent advances in understanding the biology of marginal zone lymphoma
  23. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
  24. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias
  25. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
  26. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
  27. Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas
  28. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
  29. Tailoring treatment for MALT lymphoma patients: where do we stand now?
  30. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranoda...
  31. A MALT lymphoma prognostic index
  32. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
  33. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions
  34. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
  35. Unmet needs in the scientific approach to older patients with lymphoma
  36. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study
  37. Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015
  38. Report of the 6th International Workshop on PET in lymphoma
  39. In Reply to Adams and Kwee
  40. Clinical aspects and therapy of gastrointestinal MALT lymphoma
  41. Marginal zone lymphomas: Reconsidering similarities and differences while moving towards personalized treatment
  42. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
  43. Rituximab: 13 open questions after 20years of clinical use
  44. Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma
  45. The landscape of new drugs in lymphoma
  46. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
  47. SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW
  48. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
  49. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  50. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study
  51. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strongin vivoantitumor activity in lymphoma
  52. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
  53. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
  54. Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
  55. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
  56. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
  57. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
  58. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
  59. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
  60. Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group
  61. Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know?
  62. Reply to G. Keramida et al
  63. Histologic transformation in marginal zone lymphomas
  64. Life expectancy of young adults with follicular lymphoma
  65. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma
  66. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)
  67. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
  68. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models
  69. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)
  70. A Case of Hodgkin Lymphoma in a Patient with a History of Bone Pain and an Initial Diagnosis of Chronic Osteomyelitis
  71. Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al
  72. Primary and secondary bone lymphomas
  73. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
  74. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
  75. Genetic lesions in diffuse large B-cell lymphomas
  76. Management of the Marginal Zone Lymphomas
  77. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
  78. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas
  79. In Reply
  80. Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas
  81. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas
  82. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
  83. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
  84. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
  85. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis
  86. [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study
  87. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
  88. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
  89. Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)
  90. The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)
  91. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)
  92. The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone
  93. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas
  94. Prognostic impact of monocyte count at presentation in mantle cell lymphoma - response to Georgeet al
  95. Discovering Subgroups of Patients from DNA Copy Number Data Using NMF on Compacted Matrices
  96. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  97. Open questions in the management of mantle cell lymphoma
  98. Ten Years of International Primary CNS Lymphoma Collaborative Group Studies
  99. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma
  100. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
  101. Treatment for patients with indolent and mantle cell lymphoma
  102. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)
  103. Toward New Treatments for Mantle-Cell Lymphoma?
  104. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma
  105. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ fromde novodiffuse large B-cell lymphoma
  106. The changing paradigm of chronic lymphocytic leukemia management
  107. Prognostic impact of monocyte count at presentation in mantle cell lymphoma
  108. Genome-wide high resolution DNA profiling of hairy cell leukaemia
  109. Extranodal NK/T-cell lymphoma with leukaemic presentation
  110. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study
  111. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
  112. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
  113. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
  114. Risk factors of central nervous system relapse in mantle cell lymphoma
  115. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study
  116. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH
  117. Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas
  118. Gains ofCCND3gene in ocular adnexal MALT lymphomas: an integrated analysis
  119. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
  120. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice
  121. 18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
  122. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy
  123. Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial
  124. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
  125. Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells
  126. MYD88 somatic mutations in MALT lymphomas
  127. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer
  128. Incidence, risk factors and outcome of histological transformation in follicular lymphoma
  129. Primary Bone Marrow Lymphoma
  130. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
  131. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
  132. Absence of NOTCH1 gene mutations in MALT lymphomas
  133. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array
  134. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group
  135. Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma
  136. Diagnosis and treatment of follicular lymphoma
  137. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
  138. First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial
  139. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion
  140. Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype
  141. Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines
  142. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
  143. Genomic profiles of MALT lymphomas: variability across anatomical sites
  144. Integrated profiling of diffuse large B‐cell lymphoma with 7q gain
  145. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas
  146. Epidemiology and management of lymphoma in low‐income countries
  147. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome
  148. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
  149. Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination
  150. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study
  151. Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and compar...
  152. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
  153. Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
  154. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma
  155. Syk expression patterns differ among B-cell lymphomas
  156. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21
  157. Flows and flaws in primary central nervous system lymphoma
  158. Marginal zone lymphomas
  159. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia
  160. Treatment of gastric marginal zone lymphoma of MALT type
  161. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  162. Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms
  163. IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia
  164. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma
  165. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial
  166. Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
  167. Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells
  168. Genome wide DNA-profiling of HIV-related B-cell lymphomas
  169. Response: CNS prophylaxis in MCL
  170. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas
  171. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group
  172. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
  173. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
  174. How I treat mantle cell lymphoma
  175. Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
  176. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
  177. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
  178. Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern Switzerland
  179. The NF- B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
  180. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type
  181. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study
  182. Chlorambucilversusobservation after anti-Helicobactertherapy in gastric MALT lymphomas: results of the international randomised LY03 trial
  183. Extrinsic compression of the pulmonary artery by primary mediastinal large B-cell lymphoma
  184. Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy aloneversuschemotherapy + involved field radiotherapy
  185. First-line treatment of follicular lymphoma–a patient-oriented algorithm
  186. Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?
  187. Marginal Zone Lymphomas
  188. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma
  189. The impact of histopathologic diagnosis on the proper management of testis neoplasms
  190. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion
  191. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma
  192. Primary testicular lymphoma
  193. Challenging issues in the management of extranodal lymphomas
  194. Extranodal Lymphomas
  195. Gastrointestinal tract lymphomas
  196. Who should receive myeloablative therapy for diffuse large B-cell lymphoma?
  197. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS
  198. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
  199. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
  200. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group
  201. Primary testicular lymphoma
  202. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
  203. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review
  204. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment
  205. Primary CNS Lymphomas Prognosis
  206. Marginal-zone lymphoma
  207. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas
  208. Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting
  209. Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases
  210. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
  211. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions
  212. Revised Response Criteria for Malignant Lymphoma
  213. Epidemiology of hematological malignancies
  214. Management of elderly patients with hematological neoplasms
  215. Bendamustine in lymphomas: More to combine?
  216. ConcomitantMYCand microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma
  217. Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type
  218. Low prevalence ofChlamydia psittaciin ocular adnexal lymphomas from Cuban patients
  219. A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals
  220. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?
  221. Chlamydia or Not Chlamydia, That Is the Question: Which Is the Microorganism Associated With MALT Lymphomas of the Ocular Adnexa?
  222. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas
  223. Marginal Zone B-Cell Lymphomas
  224. Delving deeper into MALT lymphoma biology
  225. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
  226. Primary Pulmonary Lymphoma: Current Status
  227. State-of-the-Art Therapeutics: Marginal-Zone Lymphoma
  228. Another Piece of the MALT Lymphomas Jigsaw
  229. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
  230. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
  231. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy
  232. Mantle cell lymphoma
  233. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’1
  234. Follicular Lymphoma International Prognostic Index
  235. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma
  236. ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis
  237. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
  238. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
  239. Molecular basis of mantle cell lymphoma
  240. Pathobiology of Primary Mediastinal B-Cell Lymphoma
  241. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
  242. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma
  243. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
  244. International Collaborative Group Against Primary CNS Lymphomas
  245. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
  246. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
  247. Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients
  248. ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma
  249. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group
  250. Primary Mediastinal B-Cell Lymphoma
  251. Mantle Cell Lymphoma: New Treatments Targeted to the Biology
  252. Treatment of extranodal lymphomas
  253. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies
  254. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial
  255. Relevance of intraocular involvement in the management of primary central nervous system lymphomas
  256. Genetic alterations underlying the pathogenesis of MALT lymphoma
  257. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies
  258. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes
  259. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
  260. Localized non-Hodgkin's lymphoma of Waldeyer's ring: Clinical features, management, and prognosis of 130 adult patients
  261. Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 66 patients
  262. Analysis ofFas/CD95 gene somatic mutations in ovarian cancer cell lines
  263. BCL10 gene mutations rarely occur in lymphoid malignancies
  264. Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma
  265. Association of gastric and Waldeyer's ring lymphoma: a molecular study
  266. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas
  267. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin
  268. Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAlu— Polymerase Chain Reaction
  269. Prognostic models for diffuse large b-cell lymphoma
  270. Extranodal lymphomas
  271. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma
  272. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study
  273. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites
  274. Microsatellite instability in gastric MALT lymphomas and other associated neoplasms
  275. Molecular Genetics of Extranodal Marginal Zone (MALT-Type) B-Cell Lymphoma
  276. Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma
  277. Primary Mediastinal Large B-Cell Lymphoma: The Need for Prospective Controlled Clinical Trials
  278. Primary Mediastinal Large B-Cell Lymphoma (PMLCL): The Need for Prospective Controlled Clinical Trials
  279. ChlVPP/ABV-VP16 Hybrid Regimen for Advanced Hodgkin's Disease: a Study in 36 Patients
  280. Clonality Assessment in Blood of Patients with Mantle Cell Lymphoma
  281. Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature
  282. Report of the European Task Force on Lymphomas: Workshop on peripheral T-cell lymphomas
  283. Therapeutic use of monoclonal antibodies: A new era?
  284. Distribution of Mobilized Progenitor Cells in the Buffy Coat of the Haemonetics MCS3p Cell Separator: A Study to Optimize the Collection of Progenitors by Leukapheresis
  285. Molecular Analysis of the Progression from Helicobacter pylori –Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach
  286. Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach
  287. Gastric Mucosa-Associated Lymphoid Tissue Lymphomas: More Than a Fascinating Model
  288. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas
  289. Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature
  290. Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma
  291. Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process
  292. Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT Lymphoma
  293. Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas
  294. 6 Gut lymphomas
  295. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphoma
  296. Biology and treatment of MALT lymphoma: The state-of-the-art in 1996
  297. Cell cycle regulation and the function of cancer genes
  298. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma
  299. Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue
  300. Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma
  301. Patterns of survival in mantle cell lymphoma
  302. Book review
  303. Book review
  304. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL)
  305. Treatment and Prognosis of Centrocytic (Mantle Cell) Lymphoma: A Retrospective Analysis of Twenty-six Patients Treated in One Institution
  306. Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis
  307. Book review
  308. Direct sequence analysis of 14q+ and 18q- chromosome junctions at the MBR and MCR revealing clustering within the MBR in follicular lymphoma
  309. Enzymuria in Carboplatin Nephrotoxicity
  310. Polarographic Assay of Submicrogram Quantities of Cis-Dichlorodiamineplatinum (II) in Biological Samples
  311. MALT and other marginal zone lymphomas